Literature DB >> 12649266

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.

Marty W Mayo1, Chadrick E Denlinger, Robert M Broad, Fan Yeung, Eugene T Reilly, Yang Shi, David R Jones.   

Abstract

Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer agents for the treatment of solid and hematological malignancies. Although HDAC inhibitors induce cell death through an apoptotic process, little is known about the molecular events that control their effectiveness. In this study, we demonstrate that HDAC inhibitors are limited in their ability to induce apoptosis in non-small cell lung cancer (NSCLC) cell lines despite their ability to effectively inhibit deacetylase activity. Because the anti-apoptotic transcription factor NF-kappa B has been shown to be under the control of HDAC-mediated repression, we analyzed whether HDAC inhibitors activated NF-kappa B in NSCLC cells. HDAC inhibitors effectively stimulated endogenous NF-kappa B-dependent gene expression by up-regulating IL-8, Bcl-XL, and MMP-9 transcripts. The ability of HDAC inhibitors to increase NF-kappa B transcriptional activity was not associated with signaling events that stimulated nuclear translocation, but rather modulated the transactivation potential of the RelA/p65 subunit of NF-kappa B. The inhibition of HDAC activity was associated with the recruitment of the p300 transcriptional co-activator to chromatin in an Akt-dependent manner. Moreover, Akt directly phosphorylated p300 in vitro and was required for stimulating the transactivation potential of the co-activator following the addition of HDAC inhibitors. Selective inhibition of either the phosphoinositide 3-kinase/Akt pathway, or NF-kappa B itself blocked the ability of HDAC inhibitors to activate NF-kappa B and dramatically sensitized NSCLC cells to apoptosis following of the addition of HDAC inhibitors. Our study indicates that the ineffectiveness of HDAC inhibitors to induce apoptosis in NSCLC cancer cells is associated with the ability of these molecules to stimulate NF-kappa B-dependent transcription and cell survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649266     DOI: 10.1074/jbc.M211695200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

2.  Transducin β-like protein 1 recruits nuclear factor κB to the target gene promoter for transcriptional activation.

Authors:  Sivakumar Ramadoss; Jiong Li; Xiangming Ding; Khalid Al Hezaimi; Cun-Yu Wang
Journal:  Mol Cell Biol       Date:  2010-12-28       Impact factor: 4.272

3.  Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity.

Authors:  Wei-Chien Huang; Ching-Chow Chen
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

4.  Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Authors:  Sofia R Gameiro; Jorge A Caballero; James W Hodge
Journal:  Cancer Biother Radiopharm       Date:  2012-02-08       Impact factor: 3.099

5.  Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.

Authors:  Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

6.  Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers.

Authors:  Tatjana Mijatovic; Véronique Mathieu; Jean-François Gaussin; Nancy De Nève; Fabrice Ribaucour; Eric Van Quaquebeke; Patrick Dumont; Francis Darro; Robert Kiss
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 7.  Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Authors:  Jürgen Sonnemann; Jennifer Gänge; K Saravana Kumar; Cornelia Müller; Peter Bader; James F Beck
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

8.  Synthesis of sulfonamides and evaluation of their histone deacetylase (HDAC) activity.

Authors:  Seikwan Oh; Hyung-In Moon; Il-Hong Son; Jae-Chul Jung; Mitchell A Avery
Journal:  Molecules       Date:  2007-05-24       Impact factor: 4.411

9.  Inhibition of NF-kappaB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes.

Authors:  P Papeleu; A Wullaert; G Elaut; T Henkens; M Vinken; G Laus; D Tourwé; R Beyaert; V Rogiers; T Vanhaecke
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

Review 10.  MHC class II regulation by epigenetic agents and microRNAs.

Authors:  Thomas B Tomasi; William J Magner; Jennifer L Wiesen; Julian Z Oshlag; Felicia Cao; Alex N Pontikos; Christopher J Gregorie
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.